Stock comparison
Novartis AG is 155.5x more valuable than Zymeworks Inc. by market capitalization ($293.95 B vs $1.89 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
NVS is larger
Novartis AG is 155.5x more valuable than Zymeworks Inc. by market capitalization ($293.95 B vs $1.89 B).
Market value leader
NVS
Novartis AG is 155.5x more valuable than Zymeworks Inc. by market capitalization ($293.95 B vs $1.89 B).
| Metric | ZYME | NVS |
|---|---|---|
| Market cap | $1.89 B | $293.95 B |
| US-listed rank | #2186 | #47 |
| Revenue (latest FY) | $105.97M | - |
| Net income (latest FY) | -$81.13M | - |
| Net margin | -76.6% | - |
| P/E (trailing FY) | - | - |
| SEC filings | 323 | 981 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Novartis AG is 155.5x more valuable than Zymeworks Inc. by market capitalization ($293.95 B vs $1.89 B).
Full pages: Zymeworks Inc. and Novartis AG, or browse the full rankings.